Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9492832rdf:typepubmed:Citationlld:pubmed
pubmed-article:9492832lifeskim:mentionsumls-concept:C0278779lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C0006118lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C0020823lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C0031928lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C1873776lld:lifeskim
pubmed-article:9492832lifeskim:mentionsumls-concept:C0556917lld:lifeskim
pubmed-article:9492832pubmed:issue3lld:pubmed
pubmed-article:9492832pubmed:dateCreated1998-3-11lld:pubmed
pubmed-article:9492832pubmed:abstractTextIfosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor. ICE therapy was administered in doses of Ifosfamide 1,800 mg/m2 x 5, Carboplatin 400 mg/m2 x 2 and Etoposide 100 mg/m2 x 5. A total of 30 courses were administered. Two cases of osteosarcoma had a stable disease (range, 3-9 months) and 2 cases of brain tumor had a complete response by magnetic resonance imaging. Moderate or severe toxicity evaluated on a per course basis included: neutropenia 83%, thrombocytopenia 93%, fever 30%, hepatotoxicity 3%, and hemorrhagic cystitis 3%. The median time to hematologic recovery was 20 days. ICE therapy is highly effective for the treatment of refractory or recurrent solid tumors with acceptable toxicity.lld:pubmed
pubmed-article:9492832pubmed:languagejpnlld:pubmed
pubmed-article:9492832pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492832pubmed:citationSubsetIMlld:pubmed
pubmed-article:9492832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492832pubmed:statusMEDLINElld:pubmed
pubmed-article:9492832pubmed:monthFeblld:pubmed
pubmed-article:9492832pubmed:issn0385-0684lld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:SatoTTlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:KobayashiSSlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:KonnoKKlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:KitagawaSSlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:TakeuchiMMlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:FujimotoTTlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:HirotaTTlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:SawadaKKlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:IwataAAlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:HamaguchiNNlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:AgataHHlld:pubmed
pubmed-article:9492832pubmed:authorpubmed-author:KatanoNNlld:pubmed
pubmed-article:9492832pubmed:issnTypePrintlld:pubmed
pubmed-article:9492832pubmed:volume25lld:pubmed
pubmed-article:9492832pubmed:ownerNLMlld:pubmed
pubmed-article:9492832pubmed:authorsCompleteYlld:pubmed
pubmed-article:9492832pubmed:pagination385-90lld:pubmed
pubmed-article:9492832pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:meshHeadingpubmed-meshheading:9492832-...lld:pubmed
pubmed-article:9492832pubmed:year1998lld:pubmed
pubmed-article:9492832pubmed:articleTitle[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].lld:pubmed
pubmed-article:9492832pubmed:affiliationDept. of Pediatrics, Aichi Medical University.lld:pubmed
pubmed-article:9492832pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9492832pubmed:publicationTypeEnglish Abstractlld:pubmed